F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Lobbying for F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough